 |
|
|
| |
Differences in Demographics and HIV Risk Exposures Among People Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Versus Other Post-Exposure Prophylaxis Regimens in the United States, 2016-2025
|
| |
| |
IDSA 2026 Wash DC Oct 21-24
Download the PDF here
Kenneth H Mayer1, Travis Lim2, Valentina Shvachko2, Laura M Mann3, Wenyi Wang2, Jason T Hindman2
1Fenway Health, Boston, MA, USA; 2Gilead Sciences, Inc., Foster City, CA, USA; 3IQVIA, Atlanta, GA, USA
|
| |
|
|
|
|
|
